BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Treatment
249 results:

  • 1. Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness.
    Lin Q; Serratore A; Niu J; Shen S; Roy Chaudhuri T; Ma WW; Qu J; Kandel ES; Straubinger RM
    Drug Resist Updat; 2024 Mar; 73():101064. PubMed ID: 38387284
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer.
    Lutz MS; Wang K; Jung G; Salih HR; Hagelstein I
    Front Immunol; 2024; 15():1343929. PubMed ID: 38322253
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Nanoparticle Targeting in Chemo-Resistant Ovarian cancer Reveals Dual Axis of Therapeutic Vulnerability Involving Cholesterol Uptake and Cell Redox Balance.
    Wang Y; Calvert AE; Cardenas H; Rink JS; Nahotko D; Qiang W; Ndukwe CE; Chen F; Keathley R; Zhang Y; Cheng JX; Thaxton CS; Matei D
    Adv Sci (Weinh); 2024 Apr; 11(13):e2305212. PubMed ID: 38263873
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Altered histone acetylation patterns in pancreatic cancer cell lines induce subtype‑specific transcriptomic and phenotypical changes.
    Zhou Q; Pichlmeier S; Denz AM; Schreiner N; Straub T; Benitz S; Wolff J; Fahr L; Del Socorro Escobar Lopez M; Kleeff J; Mayerle J; Mahajan UM; Regel I
    Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38240084
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7.
    Heublein S; Pfisterer J; du Bois A; Anglesio M; Aminossadati B; Bhatti I; Sehouli J; Wimberger P; Schochter F; Hilpert F; Hillemanns P; Kalder M; Schroeder W; Mahner S; Burges A; Canzler U; Gropp-Meier M; Jackisch C; Harter P; Kommoss S; Marmé F
    Lab Invest; 2024 Apr; 104(4):100321. PubMed ID: 38154497
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. EBF2 Links KMT2D-Mediated H3K4me1 to Suppress Pancreatic cancer Progression via Upregulating KLLN.
    Yao B; Xing M; Meng S; Li S; Zhou J; Zhang M; Yang C; Qu S; Jin Y; Yuan H; Zen K; Ma C
    Adv Sci (Weinh); 2024 Jan; 11(2):e2302037. PubMed ID: 38015024
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Expression of fibroblast growth factor receptor 1 correlates inversely with the efficacy of single-agent fibroblast growth factor receptor-specific inhibitors in pancreatic cancer.
    Lin Q; Serratore A; Perri J; Roy Chaudhuri T; Qu J; Ma WW; Kandel ES; Straubinger RM
    Br J Pharmacol; 2024 May; 181(9):1383-1403. PubMed ID: 37994108
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant cancers with B7-H4 Expression.
    Gitto SB; Whicker M; Davies G; Kumar S; Kinneer K; Xu H; Lewis A; Mamidi S; Medvedev S; Kim H; Anderton J; Tang EJ; Ferman B; Coats S; Wilkinson RW; Brown E; Powell DJ; Simpkins F
    Clin Cancer Res; 2024 Apr; 30(8):1567-1581. PubMed ID: 37882675
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Combination
    Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E
    Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898
    [No Abstract]    [Full Text] [Related]  

  • 10. Highly proliferative and hypodifferentiated CAR-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers.
    Zhang X; Guo H; Chen J; Xu C; Wang L; Ke Y; Gao Y; Zhang B; Zhu J
    Cancer Lett; 2023 Sep; 572():216355. PubMed ID: 37597651
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models.
    Wang T; Zhang K; You F; Ma R; Yang N; Tian S; An G; Yang L
    Life Sci; 2023 Oct; 331():122024. PubMed ID: 37574043
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Fibronectin fragments generated by pancreatic trypsin act as endogenous inhibitors of pancreatic tumor growth.
    Resovi A; Persichitti P; Brunelli L; Minoli L; Borsotti P; Garattini G; Tironi M; Dugnani E; Redegalli M; De Simone G; Pastorelli R; Bani MR; Piemonti L; Mosher DF; Giavazzi R; Taraboletti G; Belotti D
    J Exp Clin Cancer Res; 2023 Aug; 42(1):201. PubMed ID: 37559126
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Discovery of a pyrrole-pyridinimidazole derivative as novel SIRT6 inhibitor for sensitizing pancreatic cancer to gemcitabine.
    Song N; Guan X; Zhang S; Wang Y; Wang X; Lu Z; Chong D; Wang JY; Yu R; Yu W; Jiang T; Gu Y
    Cell Death Dis; 2023 Aug; 14(8):499. PubMed ID: 37542062
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinoma.
    Bitler BG; Bailey CA; Yamamoto TM; McMellen A; Kim H; Watson ZL
    Mol Carcinog; 2023 Nov; 62(11):1717-1730. PubMed ID: 37493106
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. All you need to know about gastrinoma today | Gastrinoma and Zollinger-Ellison syndrome: A thorough update.
    Chatzipanagiotou O; Schizas D; Vailas M; Tsoli M; Sakarellos P; Sotiropoulou M; Papalambros A; Felekouras E
    J Neuroendocrinol; 2023 Apr; 35(4):e13267. PubMed ID: 37042078
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. The stromal tumor-infiltrating lymphocytes, cancer stemness, epithelial-mesenchymal transition, and B7-H4 expression in ovarian serous carcinoma.
    Hwang C; Lee HJ; Na JY; Kim KH; Song YJ; Kim JY; Kim K; Shin DH; Park JY; Kim SY; Lee JH; Choi KU
    J Ovarian Res; 2023 Jan; 16(1):3. PubMed ID: 36609273
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. The histone deacetylase inhibitor M344 as a multifaceted therapy for pancreatic cancer.
    Knoche SM; Brumfield GL; Goetz BT; Sliker BH; Larson AC; Olson MT; Poelaert BJ; Bavari A; Yan Y; Black JD; Solheim JC
    PLoS One; 2022; 17(9):e0273518. PubMed ID: 36126055
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. CpG-binding protein CFP1 promotes ovarian cancer cell proliferation by regulating BST2 transcription.
    Yang LQ; Hu HY; Han Y; Tang ZY; Gao J; Zhou QY; Liu YX; Chen HS; Xu TN; Ao L; Xu Y; Che X; Jiang YB; Xu CW; Zhang XC; Jiang YX; Heger M; Wang XM; Cheng SQ; Pan WW
    Cancer Gene Ther; 2022 Dec; 29(12):1895-1907. PubMed ID: 35864225
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Hyperglycemia Enhances Immunosuppression and Aerobic Glycolysis of Pancreatic cancer Through Upregulating Bmi1-UPF1-HK2 Pathway.
    Wu S; Zhang H; Gao C; Chen J; Li H; Meng Z; Bai J; Shen Q; Wu H; Yin T
    Cell Mol Gastroenterol Hepatol; 2022; 14(5):1146-1165. PubMed ID: 35863742
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Histone deacetylase inhibitor, panobinostat, exerts anti-proliferative effect with partial normalization from aberrant epigenetic states on granulosa cell tumor cell lines.
    Hazama Y; Tsujioka T; Kitanaka A; Tohyama K; Shimoya K
    PLoS One; 2022; 17(7):e0271245. PubMed ID: 35802681
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 13.